Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease

Christie M. Ballantyne; Günter A.J. Riegger; Nicholas Moore; Francesco Saia; Patrick W. Serruys

doi:10.1023/b:card.0000025757.14093.e0

Related publications

Article2003

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Pedro A. Lemos, G. Boxho, Dick Goedhart, Brian J. O’Neil, J. P. Broustet, Gunnar H. Berghoefer, C. Alonso, A. Boehmer, Pim de Feyter, Patrick W. Serruys

Journal of the American College of Cardiology

Article1983

Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behavior in patients with coronary heart disease.

Patrick W. Serruys, I Stoel, Paul G. Hugenholtz, Peter de Leeuw, Huib van Vliet, Hans Deckmyn, J. Vermylen, Wim van der Giessen

PubMed

Article1984

Haemodynamic effects of intravenous cibenzoline in patients with coronary heart disease

Marcel van den Brand, Patrick W. Serruys, Y. de Roon, Marie France Aymard, A Dufour

European Journal of Clinical Pharmacology

Article2006

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Patrick W. Serruys, Pim de Feyter, Carlos Macaya, N. Kokott, Jean‐Luc Puel, Matthias Vrolix, Angelo Branzi, Marcelo Chiara Bertolami, Graham Jackson, Bradley H. Strauss, Bernhard Meier

Article2004

Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease

Pedro A. Lemos, Pim J. de Feyter, Patrick W. Serruys, Francesco Saia, Chourmouzios A. Arampatzis, Clemens Disco, Nestor Mercado, Vicente Mainar, César Morı́s, Arjan A. van den Bos, Gunnar H. Berghoefer

International Journal of Cardiology